Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CDTX 
Cidara Therapeutics Inc (CDTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/26/2025: CDTX (3-star) is a STRONG-BUY. BUY since 22 days. Simulated Profits (109.01%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $209.38
1 Year Target Price $209.38
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 116.2% | Avg. Invested days 28 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/26/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.91B USD | Price to earnings Ratio - | 1Y Target Price 209.38 |
Price to earnings Ratio - | 1Y Target Price 209.38 | ||
Volume (30-day avg) 5 | Beta 1.55 | 52 Weeks Range 15.22 - 220.46 | Updated Date 11/26/2025 |
52 Weeks Range 15.22 - 220.46 | Updated Date 11/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-11-06 | When - | Estimate -2.77 | Actual -3.1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.35% | Return on Equity (TTM) -68.7% |
Valuation
Trailing PE - | Forward PE 5.75 | Enterprise Value 6489144112 | Price to Sales(TTM) 4540.7 |
Enterprise Value 6489144112 | Price to Sales(TTM) 4540.7 | ||
Enterprise Value to Revenue 0.61 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 31446306 | Shares Floating 23106366 |
Shares Outstanding 31446306 | Shares Floating 23106366 | ||
Percent Insiders 0.71 | Percent Institutions 103.71 |
Upturn AI SWOT
Cidara Therapeutics Inc
Company Overview
History and Background
Cidara Therapeutics Inc. was founded in 2012. It is a biotechnology company focused on developing novel anti-infectives.
Core Business Areas
- Antifungal Program: Focused on developing rezafungin, an echinocandin antifungal for the treatment and prevention of serious fungal infections.
Leadership and Structure
Jeffrey Stein, Ph.D., is the President and CEO. The company has a typical biotechnology organizational structure with research, development, clinical, and commercial operations.
Top Products and Market Share
Key Offerings
- Rezafungin: Rezafungin is Cidara's lead product candidate, an echinocandin antifungal. A New Drug Application (NDA) was accepted by the FDA in 2022. Competitors include other echinocandins such as caspofungin (Merck's Cancidas), micafungin (Astellas' Mycamine), and anidulafungin (Pfizer's Eraxis).
Market Dynamics
Industry Overview
The anti-infectives market is driven by the increasing prevalence of drug-resistant infections and the need for new therapies. There is a need to keep up with the evolution of resistant species.
Positioning
Cidara aims to address unmet needs in the antifungal space with Rezafungin, which offers potential advantages over existing treatments, such as once-weekly IV dosing and broad spectrum action.
Total Addressable Market (TAM)
The TAM for systemic antifungals is estimated to be in the billions of dollars annually. Cidara, if approved, is positioned to capture a portion of this market.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action
- Potential for Once-Weekly Dosing
- Strong Intellectual Property
- Experienced Management Team
Weaknesses
- Reliance on a Single Product Candidate (Rezafungin)
- Lack of Commercial Infrastructure
- Dependence on Regulatory Approval
- Significant Debt
Opportunities
- Expansion into New Indications
- Partnerships with Larger Pharmaceutical Companies
- Growing Antifungal Market
- Acquisition Potential
Threats
- Competition from Existing Antifungals
- Generic Entry of Existing Antifungals
- Regulatory Hurdles
- Clinical Trial Failures
Competitors and Market Share
Key Competitors
- MRK
- PFE
- ALPMF
Competitive Landscape
Cidara's competitive advantage lies in the potential for less frequent dosing. Disadvantages include lack of commercial experience and smaller resources compared to large pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of Rezafungin through clinical trials.
Future Projections: Future growth depends on the successful commercialization of Rezafungin and potential new indications for the product.
Recent Initiatives: Recent initiatives include completing clinical trials for Rezafungin, submitting regulatory filings, and seeking partnerships.
Summary
Cidara is a biotechnology company focused on developing Rezafungin, a novel antifungal. Its success hinges on regulatory approval and successful commercialization. The company faces challenges including reliance on a single product, competition from established players, and financial constraints. Overcoming these hurdles would position them for a significant role in the anti-infectives market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
Data is based on available information and may be subject to change. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cidara Therapeutics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2015-04-15 | President, CEO & Executive Director Dr. Jeffrey L. Stein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.cidara.com |
Full time employees 38 | Website https://www.cidara.com | ||
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.